Patent · US Active

Risperidone sustained release microsphere composition

US9532991B2 · kind B2 · utility

0Cited by

1References

19Claims

0Family size

Assignees

Inventors

Kaoxiang Sun · Yantai, CN
Rongcai Liang · Yantai, CN
Qilin Wang · Brisbane, AU
Wenyan Wang · Wilmette, US
Wanhui Liu · Yantai, CN
Youxin Li · Langenfeld, DE

Key dates

Filing date	Jul 22, 2016
Grant date	Jan 3, 2017
Priority date	—
Expiry date	Jul 22, 2036

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/16
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.